Some studies of CD19-CAR-T cell therapy, patients who showed the best clinical outcome also had increased frequency of memory T cells in their CAR-T cell product.20,27 In our study, in CAR-T cell products of the all 56 assessable DLBCL patients, the proportion of CD8+ TSCM (stem cell-like memory T cells,19,30,31 CD45RA+CD62L+) was significantly higher in response patients than in resistant patients (p < 0.0001), and patients in the high quartile showed a response rate of 100% (Fig. 2c). The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.